Skip to main content

3 Result(s)

within M. E. Cazzaniga Remove this filter Oncology Remove this filter

and

  1. Article

    Open Access

    Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study

    Tregs are able of suppressing tumor-specific effector cells, such as lymphocytes CD8+, CD4+ and Natural Killer cells. Different drugs, especially different schedules of administration, like metronomic chemothe...

    F. F. Pepe, M. E. Cazzaniga, S. Baroni, F. Riva, F. Cicchiello, S. Capici… in BMC Cancer (2022)

    Download PDF (1347 KB) View Article

  2. Article

    Open Access

    Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

    Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2):...

    M. E. Cazzaniga, I. Vallini, E. Montagna… in Breast Cancer Research and Treatment (2021)

    Download PDF (1381 KB) View Article

  3. Article

    Open Access

    Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

    The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 st...

    M. E. Cazzaniga, L. Cortesi, A. Ferzi, L. Scaltriti… in Breast Cancer Research and Treatment (2016)

    Download PDF (588 KB) View Article